Cardio Research, s.r.o

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Obesity4 trials
• Heart failure3 trials
• Atrial fibrillation2 trials
• Stroke2 trials
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Peripheral artery disease1 trial
• Type 2 diabetes1 trial

Phase

• Phase 37 trials

Status

• Active, not recruiting3 trials
• Recruiting3 trials
• Completed1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• Novo Nordisk A/S2 trials
• Bayer AG1 trial
• Boehringer Ingelheim1 trial
• Janssen Research & Development, LLC1 trial

Running trials

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure2 recruiting
• Obesity2 recruiting

Closed trials

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source